

## Chapter CSB 4

## PRESCRIPTION DRUG MONITORING PROGRAM

CSB 4.01	Authority and scope.	CSB 4.08	Exemptions from compiling and submitting dispensing data.
CSB 4.02	Definitions.	CSB 4.09	Direct access to PDMP information.
CSB 4.03	Drugs that have a substantial potential for abuse.	CSB 4.10	Requests for review.
CSB 4.04	Compilation of dispensing data.	CSB 4.11	Methods of obtaining PDMP information.
CSB 4.05	Electronic submission of dispensing data.	CSB 4.12	Use of PDMP information by the board and department.
CSB 4.06	Frequency of submissions.	CSB 4.13	Confidentiality of PDMP information.
CSB 4.07	Correction of dispensing data.	CSB 4.14	Exchange of PDMP information.

**Note:** Chapter Phar 18 was renumbered chapter CSB 4 under s. 13.92 (4) (b) 1., Stats., Register September 2015 No. 717.

**CSB 4.01 Authority and scope.** The rules in this chapter are adopted under authority in ss. 227.11 (2) (a) and 961.385, Stats., for the purpose of creating a prescription drug monitoring program to collect and maintain information relating to the prescribing and dispensing of prescription drugs.

**History:** CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; correction made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.02 Definitions.** As used in this chapter:

(1) "Access" means to have the ability to view PDMP information through an account established with the board.

(2) "Administer" has the meaning given in s. 450.01 (1), Stats.

(3) "Animal" has the meaning given in s. 89.02 (1m), Stats.

(3m) "ASAP" means the American Society for Automation in Pharmacy.

**Note:** Contact: American Society for Automation in Pharmacy, 492 Norristown Road, Suite 160; Blue Bell, PA 19422; phone: (610) 825-7783; fax: (610) 825-7641; webpage: <http://asapnet.org/index.html>.

(4) "Board" has the meaning given in s. 450.01 (2), Stats.

(5) "Controlled substance" means a drug, substance, analog, or precursor described in any of the following:

(a) Schedule I, II, III, IV, or V in the federal controlled substances act, 21 USC 812 (b) (1) to (b) (5) and (c), as changed and updated by 21 CFR 1308.

(b) Schedule I, II, III, IV, or V in subch. II of ch. 961, Stats., as amended by ch. CSB 2.

(6) "Department" means the department of safety and professional services.

(7) "Dispense" has the meaning given in s. 450.01 (7), Stats.

(8) "Dispenser" means all of the following:

(a) A pharmacy.

**Note:** A site of remote dispensing authorized under s. 450.062, Stats., and s. Phar 7.095 is under the supervision of a pharmacy.

(b) A practitioner who dispenses a monitored prescription drug.

(9) "Dispenser delegate" means any of the following:

(a) A managing pharmacist of a pharmacy.

(b) An agent or employee of a practitioner who has been delegated the task of satisfying the data compilation and submission requirements of ss. CSB 4.04 and 4.05.

(10) "Dispensing data" means data compiled pursuant to s. CSB 4.04.

(11) "Drug" has the meaning given in s. 450.01 (10), Stats.

(11g) "Hospital" has the meaning given in s. 50.33 (2), Stats.

(11r) "Managing pharmacist" has the meaning given in s. Phar 1.02 (6).

(12) (a) "Monitored prescription drug" means all of the following:

1. A controlled substance included in s. 961.385 (1), Stats.

2. A drug identified by the board as having a substantial potential for abuse in s. CSB 4.03.

(b) "Monitored prescription drug" does not mean a controlled substance that by law may be dispensed without a prescription order.

(13) "Patient" has the meaning given in s. 450.01 (14), Stats.

(14) "Person authorized by the patient" means person authorized by the patient in s. 146.81 (5), Stats., and includes persons with delegated authority under s. 48.979, Stats.

(14e) "PDMP" means the Wisconsin prescription drug monitoring program.

(15) "PDMP information" means any of the following:

(a) The data compiled and stored by the board from dispensing data submitted to it by dispensers.

(b) The information created by the board to satisfy the requirements in s. CSB 4.12.

(15g) "Pharmacist" has the meaning given in s. 961.385 (1) (aL), Stats.

(15r) "Pharmacist delegate" means an agent of a pharmacist to whom the pharmacist has delegated the task of accessing PDMP information.

(16) "Pharmacy" means any place of practice licensed by the board under ss. 450.06 or 450.065, Stats., including a pharmacy that chooses to solely dispense to animal patients.

(17) "Practitioner" has the meaning given in s. 961.385 (1) (ar), Stats.

(18) "Practitioner delegate" means an agent or employee of a practitioner to whom the practitioner has delegated the task of accessing PDMP information.

(19) "Prescription" has the meaning given in s. 450.01 (19), Stats.

(20) "Prescription order" has the meaning given in s. 961.385 (1) (b), Stats.

(21) "Program" means the prescription drug monitoring program established under this chapter.

(23) "Zero report" means a report that indicates that a dispenser has not dispensed a monitored prescription drug since the previous submission of dispensing data or a zero report.

**History:** CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; correction in (5) (b) made under s. 13.92 (4) (b) 7., Stats., Register October 2012 No. 682; CR 13-065: cr. (3m), (13e), am. (16), (17), r. (22) Register February 2014 No. 698, eff. 3-1-14; (13e) renum. to (14e) under s. 13.92 (4) (b) 1., Stats., Register February 2014 No. 698; correction in (17) made under s. 13.92 (4) (b) 7., Stats., Register February 2014 No. 698; CR 14-003: am. (8) (a), renum. (9) to (9) (intro.) and am., cr. (9) (a), (b), (11g), (11r), am. (15) (intro.), cr. (15g), (15r), am. (17) Register August 2014 No. 704, eff. 9-1-14; correction in (3), (9) (b), (10), (12) (a) 1., 2., (15) (b), (15g), (17), (20) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.03 Drugs that have a substantial potential for abuse.** Pursuant to s. 961.385 (1) (ag), Stats., the board has identified all of the following drugs as having a substantial potential for abuse:

(1) A controlled substance identified in schedule II, III, IV or V in the federal controlled substances act, 21 USC 812 (b) (2) to (b) (5) and (c), as changed and updated by 21 CFR 1308.

(2) A controlled substance identified in schedule IV or V in subch. II of ch. 961, Stats., as amended by ch. CSB 2.

**(3) Tramadol.**

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; correction in (2) made under s. 13.92 (4) (b) 7., Stats., Register October 2012 No. 682; CR 13–065: am. (intro.) Register February 2014 No. 698, eff. 3–1–14; correction in (intro.) made under s. 13.92 (4) (b) 7., Stats., Register February 2014 No. 698; correction in (intro.) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.04 Compilation of dispensing data. (1)** As used in this section:

(a) “DEA registration number” means the registration number issued to a dispenser or practitioner by the federal department of justice, drug enforcement administration.

(b) “Dispenser identifier” means the DEA registration number or when the DEA registration number is not available, the NPI number.

(c) “NDC number” means national drug code number, the universal product identifier used in the U.S. to identify a specific drug product.

(d) “NPI number” means national provider identifier number, the registration number issued to a dispenser or practitioner by the national provider identifier registry.

(e) “Practitioner identifier” means the DEA registration number or when the DEA registration number is not available, the NPI number.

**(2)** Subject to s. CSB 4.08, a dispenser shall compile dispensing data that contains all of the following information each time the dispenser dispenses a monitored prescription drug:

- (a) The dispenser’s full name.
- (b) The dispenser identifier, if available.
- (c) The date dispensed.
- (d) The prescription number.
- (e) The NDC number or the name and strength of the monitored prescription drug.
- (f) The quantity dispensed.
- (g) The estimated number of days of drug therapy.
- (ge) The classification code for payment type.
- (gm) The number of refills authorized by the prescriber.
- (gs) The refill number of the prescription.
- (h) The practitioner’s full name.
- (i) The practitioner identifier, if available.
- (j) The date prescribed.
- (L) The patient’s full name or if the patient is an animal, the animal’s name and the owner’s last name.
- (m) The patient’s address, or if the patient is an animal, patient’s owner’s address, including street address, city, state, and ZIP code.
- (n) The patient’s date of birth, or if the patient is an animal, patient’s owner’s date of birth.
- (o) The patient’s gender.
- (p) The name recorded under s. 450.11 (1b) (bm), Stats.

**Note:** This paragraph is created effective 4–9–17.

**(4)** A dispenser and dispenser delegate, if applicable, who fail to compile dispensing data as required by sub. (2) may be subject to disciplinary action by the licensing board that issued the license under which the dispenser is authorized to dispense monitored prescription drugs.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 13–065: am. (1) (b), (e), (3) (b), (d), (i), (k) Register February 2014 No. 698, eff. 3–1–14; CR 14–003: am. (title), renum. (2) to (2) (intro.) and am., cr. (2) (ge), (gm), (gs), renum. (3) (a) to (g) and (h) to (j) to (2) (a) to (g) and (h) to (j), r. (3) (k), renum. (3) (L) to (o) to (o) and am. (L) to (n), am. (4) Register August 2014 No. 704, eff. 9–1–14; correction in (2) (intro.) made under s. 35.17, Stats., and in (4) made under s. 13.92 (4) (b) 7., Stats., Register August 2014 No. 704; correction in (2) (intro.) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717; **CR 15–070: cr. (2) (p) Register April 2016 No. 724, eff. 4–9–17; numbering correction in (2) (p) under s. 13.92 (4) (b) 1. Register April 2016 No. 724; republished to correct CR 15–070: cr. (2) (p) effective date Register May 2016 No. 725.**

**CSB 4.05 Electronic submission of dispensing data. (1)** Unless exempt under s. CSB 4.08, a dispenser shall electronically submit dispensing data through an account with the board.

**Note:** The application to create an account may be completed online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services, 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**(2)** The dispensing data shall be submitted to the board in compliance with the data standards in the version and release of ASAP implementation guide for prescription monitoring programs identified by the board or other electronic format identified by the board.

**Note:** The guide for dispensers which specifies the data standards in the version and release of the ASAP implementation guide for prescription monitoring programs identified by the board and other electronic formats identified by the board may be obtained online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services, 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**(3)** If a dispenser is not able to create an account or submit dispensing data as required by subs. (1) and (2), the board may grant a waiver to a dispenser who satisfies all of the following conditions:

(a) The dispenser agrees to begin filing dispensing data on a paper form identified by the board for each monitored prescription drug dispensed.

(b) The dispenser files with the board a written application for a waiver on a form provided by the board.

**Note:** The application for a waiver may be obtained online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services, 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**(4)** A dispenser and dispenser delegate, if applicable, who fail to create an account with the board and submit dispensing data as required by subs. (1) and (2) or be granted a waiver under sub. (3) may be subject to disciplinary action by the licensing board that issued the license under which the dispenser is authorized to dispense monitored prescription drugs.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 13–065: am. (2) Register February 2014 No. 698, eff. 3–1–14; CR 14–003: am. (1), (4) Register August 2014 No. 704, eff. 9–1–14; correction in (intro.) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.06 Frequency of submissions. (1)** A dispenser shall submit dispensing data to the board within 7 days of dispensing a monitored prescription drug.

**(2)** If a dispenser does not dispense a monitored prescription drug for 7 days, the dispenser shall submit a zero report to the board for each 7–day period during which the dispenser did not dispense a monitored prescription drug.

**(3)** If a dispenser is not able to submit dispensing data within 7 days of dispensing a monitored prescription drug as required by sub. (1), the board may grant an emergency waiver to a dispenser who satisfies all of the following conditions:

(a) The dispenser is not able to submit dispensing data because of circumstances beyond its control.

(b) The dispenser files with the board a written application for an emergency waiver on a form provided by the board prior to the required submission of dispensing data.

**Note:** The application for an emergency waiver may be obtained online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services, 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**(4)** Unless otherwise specified by the board, an emergency waiver granted under sub. (3) shall only be effective for 7 days.

**(5)** A dispenser and dispenser delegate, if applicable, who fail to submit dispensing data or a zero report as required by subs. (1) and (2), or be granted an emergency waiver under sub. (3), or a dispenser and a dispenser delegate, if applicable, who submit false information to the board may be subject to disciplinary action by the licensing board that issued the license under which the dispenser is authorized to dispense monitored prescription drugs.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 13–065: am. (1), (2), (3) (intro.), r. (4) to (6), (9), renum. (7) to (4) and am., renum. (8) to (5) Register February 2014 No. 698, eff. 3–1–14; CR 14–003: am. (2), (5) Register August 2014 No. 704, eff. 9–1–14.

**CSB 4.07 Correction of dispensing data.** If a dispenser discovers omissions or inaccuracies in previously submitted dispensing data or other PDMP information, the dispenser shall submit correct information within 7 days.

**Note:** The written notice to the board may be submitted through an account with the board, sent by electronic mail or sent by U.S. mail to the Department of Safety and Professional Services 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 14–003: am. Register August 2014 No. 704, eff. 9–1–14.

**CSB 4.08 Exemptions from compiling and submitting dispensing data.** (1) The board shall exempt a dispenser from compiling and submitting dispensing data and from submitting a zero report as required under this chapter until the dispenser is required to renew his or her license, or until the dispenser dispenses a monitored prescription drug, if the dispenser satisfies all of the following conditions:

(a) The dispenser provides evidence sufficient to the board that the dispenser does not dispense monitored prescription drugs.

(b) The dispenser files with the board a written request for exemption on a form provided by the board.

**Note:** The application for an exemption may be obtained online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or at no charge from the Department of Safety and Professional Services 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708. A dispenser who is already exempt can renew his or her exemption as part of the licensure renewal process.

(2) A dispenser is not required to compile or submit dispensing data when the monitored prescription drug is administered directly to a patient.

(3) A dispenser is not required to compile or submit dispensing data when the monitored prescription drug is a substance listed in the schedule in s. 961.22, Stats., and is not a narcotic drug, as defined in s. 961.01 (15), Stats., and is dispensed pursuant to a prescription order for a number of doses that is intended to last the patient 7 days or less.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 14–003: am. (1) (a), cr. (3) Register August 2014 No. 704, eff. 9–1–14.

**CSB 4.09 Direct access to PDMP information.**

(1) Pharmacists, pharmacist delegates, practitioners, and practitioner delegates may access PDMP information in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter and other state or federal laws and regulations relating to the privacy of patient health care records.

(2) To obtain access to PDMP information, pharmacists, pharmacist delegates, practitioners, and practitioner delegates shall do one of the following:

(a) Create an account with the board on a form provided by the board.

(b) Create an account with a prescription monitoring program operated by a relevant agency in another jurisdiction with whom the board exchanges PDMP information pursuant to s. CSB 4.14.

(c) Create an account with a pharmacy or other entity at which pharmacists dispense or administer monitored prescription drugs in the course of professional practice with which the board has determined to have at least equivalent capability to maintain the confidentiality of PDMP information or that is connected to and lawfully obtains data from the state–designated entity under ch. 153, Stats.

(d) Create an account with a hospital or other entity at which practitioners prescribe, dispense, or administer monitored prescription drugs in the course of professional practice with which the board has determined to have at least equivalent capability to maintain the confidentiality of PDMP information or that is connected to and lawfully obtains data from the state–designated entity under ch. 153, Stats.

**Note:** The application to create an account may be completed online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services, 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

(3) The board may deny, suspend, revoke or otherwise restrict or limit a pharmacist’s, pharmacist delegate’s, practitioner’s, or practitioner delegate’s direct access to PDMP information for any of the following reasons:

(a) The pharmacist, pharmacist delegate, practitioner, or practitioner delegate uses PDMP information in violation of s. 146.82 or 961.385, Stats., this chapter, or other state or federal laws or regulations relating to the privacy of patient health care records.

(b) The pharmacist, pharmacist delegate, practitioner, or practitioner delegate is no longer licensed in this state or another state and recognized by this state as a person authorized to prescribe or dispense monitored prescription drugs.

(c) The board, or other licensing board, or regulatory agency takes adverse action against the pharmacist, pharmacist delegate, practitioner, or practitioner delegate.

(d) A licensing board or equivalent regulatory agency in another jurisdiction takes adverse action against the pharmacist, pharmacist delegate, practitioner, or practitioner delegate.

(e) The federal department of justice, drug enforcement administration takes adverse action against the pharmacist, pharmacist delegate, practitioner, or practitioner delegate.

(f) The pharmacist, pharmacist delegate, practitioner, or practitioner delegate is convicted of a crime substantially related to the prescribing or dispensing of a monitored prescription drug.

(g) The pharmacist delegate or practitioner delegate is no longer delegated the task of accessing PDMP information.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 14–003: am. (1), renum. (2) to (2) (intro.) and am., cr. (2) (a) to (d), am. (3) Register August 2014 No. 704, eff. 9–1–14; corrections in (1), (2) (b), (3) (a) Register September 2015 No. 717.

**CSB 4.10 Requests for review.** (1) A pharmacist, pharmacist delegate, practitioner, or practitioner delegate may request that the board review any of the following:

(a) The denial of a waiver requested pursuant to s. CSB 4.05 (3).

(b) The denial of an emergency waiver requested pursuant to s. CSB 4.06 (3).

(c) The denial, suspension, revocation or other restriction or limitation imposed on the dispenser’s, dispenser delegate’s, practitioner’s, or practitioner delegate’s account pursuant to s. CSB 4.09 (3).

(2) To request a review, the pharmacist, pharmacist delegate, practitioner, or practitioner delegate shall file a written request with the board within 20 days after the mailing of the notice of the action in sub. (1). The request shall be in writing and include all of the following:

(a) The dispenser’s, dispenser delegate’s, practitioner’s, or practitioner delegate’s name and address, including street address, city, state and ZIP code.

(b) The citation to the specific statute or rule on which the request is based.

(3) The board shall conduct the review at its next regularly scheduled meeting and notify the pharmacist, pharmacist delegate, practitioner, or practitioner delegate of the time and place of the review.

(4) No discovery is permitted.

(5) The board shall preside over the review. The review shall be recorded by audio tape unless otherwise specified by the board.

(6) The board shall provide the pharmacist, pharmacist delegate, practitioner, or practitioner delegate with an opportunity to submit written documentation, make a personal appearance before the board and present a statement. The board may establish a time limit for making a presentation. Unless otherwise determined by the board, the time for making a personal appearance shall be 20 minutes.

(7) If the pharmacist, pharmacist delegate, practitioner, or practitioner delegate fails to appear for a review, or withdraws the

request for a review, the board may note the failure to appear in the minutes and affirm its original decision without further action.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; correction in (1) (b) made under s. 13.92 (4) (b) 7., Stats., Register February 2014 No. 698; CR 14–003: am. (1) (intro.), (2) (intro.), (b), (3), (6), (7) Register August 2014 No. 704, eff. 9–1–14; correction in (1) (a) to (c) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

#### CSB 4.11 Methods of obtaining PDMP information.

(1) The board shall disclose PDMP information about a patient to the patient if he or she does all of the following:

(a) Appears in person at the department with two forms of valid proof of identity, one of which is valid government–issued photographic identification.

(b) Makes a request for the PDMP information on a form provided by the board.

(2) The board shall disclose PDMP information about a patient to a person authorized by the patient if the person authorized by the patient does all of the following:

(a) Appears in person at the department with two forms of valid proof of identity, one of which is valid government–issued photographic identification.

(b) Provides proof sufficient to the board of the authorization or delegation from the patient.

(c) Makes a request for the PDMP information on a form provided by the board.

(5) The board shall disclose the minimum amount of PDMP information necessary to designated staff of a federal or state governmental agency in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter, and other state or federal laws and regulations relating to the privacy of patient health care records if the designated staff does all of the following:

(a) Creates an account with the board on a form provided by the board.

(b) Provides proof sufficient to the board that the federal or state governmental agency is entitled to the information under s. 146.82 (2) (a) 5., Stats.

(c) Makes a request for the PDMP information through its account with the board.

(6) The board shall disclose the minimum amount of PDMP information necessary to designated staff of the department who is charged with investigating dispensers, dispenser delegates, pharmacists, pharmacist delegates, practitioners, and practitioner delegates in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter, and other state or federal laws and regulations relating to the privacy of patient health care records if the designated staff does all of the following:

(a) Creates an account with the board on a form provided by the board.

(b) Provides proof sufficient to the board that the department is entitled to the information under s. 146.82 (2) (a) 5., Stats.

(c) Makes a request for the PDMP information through its account with the board.

(7) The board shall disclose the minimum amount of PDMP information necessary to a prisoner’s health care provider, the medical staff of a prison or jail in which a prisoner is confined, the receiving institution intake staff at a prison or jail to which a prisoner is being transferred or a person designated by a jailer to maintain prisoner medical records or designated staff of the department of corrections in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter, and other state or federal laws and regulations relating to the privacy of patient health care records if the person does all of the following:

(a) Creates an account with the board on a form provided by the board.

(b) Provides proof sufficient to the board that the person is entitled to the information under s. 146.82 (2) (a) 21., Stats.

(c) Makes a request for the PDMP information through its account with the board.

(8) The board shall disclose the minimum amount of PDMP information necessary to a coroner, deputy coroner, medical examiner, or medical examiner’s assistant following the death of a patient in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter, and other state or federal laws and regulations relating to the privacy of patient health care records if the person does all of the following:

(a) Creates an account with the board on a form provided by the board.

(b) Provides proof sufficient to the board that the person is entitled to the information under s. 146.82 (2) (a) 18., Stats.

(c) Makes a request for the PDMP information through its account with the board.

(9) The board may disclose de–identified PDMP information which does not and cannot be reasonably used to identify any patient upon written request.

(10) The board shall disclose the minimum amount of PDMP information to designated staff of a law enforcement authority in the same or similar manner, and for the same or similar purposes, as those persons are authorized to access similar confidential patient health care records under ss. 146.82 and 961.385, Stats., this chapter, and other state or federal laws and regulations relating to the privacy of patient health care records if the designated staff does all of the following:

(a) Creates an account with the board on a form provided by the board.

(b) Provides a lawful order of a court of record under s. 146.82 (2) (a) 4., Stats., or provides evidence satisfactory to the board that the law enforcement agency is entitled to the information under s. 146.82 (2) (a) 11., Stats.

(c) Makes a request for PDMP information through its account with the board.

**Note:** The application to create an account and form to request PDMP information may be completed online at [www.dsp.wi.gov](http://www.dsp.wi.gov) or obtained at no charge from the Department of Safety and Professional Services 1400 East Washington Avenue, P.O. Box 8366, Madison, WI 53708.

**History:** CR 12–009: cr. Register October 2012 No. 682, eff. 1–1–13; CR 14–003: r. (3), (4), am. (6) (intro.), renum. (9) (intro.) to (9) and am., r. (9) (a) to (c) Register August 2014 No. 704, eff. 9–1–14; correction in (5) (intro.), (6) (intro.), (7) (intro.), (8) (intro.), (10) (intro.) Register September 2015 No. 717.

**CSB 4.12 Use of PDMP information by the board and department.** (1) The board shall develop and maintain a PDMP database to store PDMP information.

(2) The PDMP database shall store PDMP information in an encrypted format.

(3) The board shall maintain a log of persons to whom the board grants access to PDMP information.

(4) The board shall maintain a log of information submitted by each dispenser.

(4g) The board shall maintain a log of information accessed by each pharmacist, pharmacist delegate, practitioner, and practitioner delegate.

(4r) The board shall maintain a log of information disclosed, including the name of the person to whom the information was disclosed.

(5) The board shall maintain a log of requests for PDMP information.

(6) Board and department staff assigned administrative duties over the PDMP, vendors, and other agents of the board shall only have access to the minimum amount of PDMP information necessary for all of the following purposes:

(a) The design, implementation, operation, and maintenance of the program, including the PDMP database, as part of the assigned duties and responsibilities of their employment.

(b) The collection of dispensing data as part of the assigned duties and responsibilities under s. 961.385, Stats., and this chapter.

(c) Evaluating and responding to legitimate requests for PDMP information.

(d) Other legally authorized purposes.

**History:** CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; CR 14-003: am. (4), cr. (4g), (4r) Register August 2014 No. 704, eff. 9-1-14; correction in (6) (b) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.13 Confidentiality of PDMP information.**

(1) The PDMP information maintained by the board, department or a vendor contracting with the department which is submitted to, maintained, or stored as a part of the program is not subject to inspection or copying under s. 19.35, Stats.

(2) A person who discloses PDMP information in violation of s. 146.82 or 961.385, Stats., this chapter, or other state or federal laws or regulations relating to the privacy of patient health care records, may be subject to disciplinary action by the licensing board that issued the license under which the person is authorized to prescribe or dispense monitored prescription drugs and all appropriate civil and criminal penalties.

**History:** CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; correction in (2) made under s. 13.92 (4) (b) 7., Stats., Register September 2015 No. 717.

**CSB 4.14 Exchange of PDMP information. (1)** The board may exchange PDMP information with a prescription monitoring program operated by a relevant agency in another state or jurisdiction if the prescription monitoring program satisfies all of the following conditions:

(a) The prescription monitoring program is compatible with the program.

(b) The relevant agency operating the prescription monitoring program agrees to exchange similar information with the program.

(2) In determining the compatibility of a prescription monitoring program to the program, the board may consider any of the following:

(a) The safeguards for privacy of patient records and the prescription monitoring program's success in protecting patient privacy.

(b) The persons authorized to access the information stored by the prescription monitoring program.

(c) The schedules of controlled substances monitored by the prescription monitoring program.

(d) The information required by the agency to be submitted regarding the dispensing of a prescription drug.

(e) The costs and benefits to the board of sharing information.

(3) The board may assess a prescription monitoring program's continued compatibility with the program at any time.

**History:** CR 12-009: cr. Register October 2012 No. 682, eff. 1-1-13; CR 14-003: am. (1) (intro.) Register August 2014 No. 704, eff. 9-1-14.